Bildkälla: Stockfoto

BioInvent: Phase IIa of BI-1808 Started - Redeye

Today, BioInvent announced the initiation of the phase IIa monotherapy part of the study of BI-1808, which we discuss in this note.

Today, BioInvent announced the initiation of the phase IIa monotherapy part of the study of BI-1808, which we discuss in this note.
Börsvärldens nyhetsbrev
ANNONSER